Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

CAN (ON): Coronavirus doesn't stop Vivo Cannabis

VIVO Cannabis has announced that the Company, its production facilities and medical clinics are continuing to respond to COVID-19 with changes to internal business practices consistent with the guidelines of public health authorities. "As VIVO continues to monitor the COVID-19 pandemic, the health and safety of its customers and employees remains the Company's top priority," the team with the company says. 

"As we navigate this ever-evolving situation, we have implemented several measures to protect our employees, while allowing us to continue to operate our business," said Barry Fishman, CEO of VIVO. "We are continuing to monitor the latest developments and the guidance from government bodies and public health authorities. Our commitment to strong corporate governance, sound business judgement and proactive actions are more important now than ever."

"For the past several weeks, VIVO has been actively monitoring COVID-19 developments and taking the necessary precautions for its business. VIVO has encouraged all employees to suspend travel, work from home when possible, and enhanced the use of personal protective equipment to reduce the risk of COVID-19 exposure and spread. The Company has also deployed more rigorous cleaning and sanitization efforts across all of its sites and continues to assess its facilities and clinics as the situation continues to evolve. At present, VIVO's production facilities are continuing operations and have no confirmed cases of COVID-19."

According to a survey of recreational cannabis users conducted by Deloitte, 59% of respondents consume at home alone. Spurred by an environment of uncertainty and anxiety, recent trends indicate that many consumers and patients are stocking-up on product in response to fears of shortages and lack of access. The Company has already seen a short-term increase in sales on its medical platform. Although this is anticipated to be temporary, it demonstrates VIVO's dedication to satisfying consumer and patient needs.

For more information:
VIVO Cannabis
vivocannabis.com    

Publication date: